JohnnyB
Community Veteran
Long™R3IGF-I
Recombinant analog of human insulin growth factor-I
CATALOG NO. 85580
Description
Long™R3IGF-I is a recombinant analog of human insulin-like growth factor-I (IGF-I) that has been specifically engineered for the enhancement of cell culture performance. Long™R3IGF-I is more biologically potent in vitro than either insulin or native IGF-I and has been documented to
significantly increase recombinant protein production. It is ideal for both research and large-scale culture systems utilizing serum-free or low-level serum applications. Long™R3IGF-I is effective in any cell that contains type I IGF receptors, including most Chinese Hamster Ovary (CHO) lines, hybridomas and fibroblasts. Long™R3IGF-I is produced in a patented E. coli expression system without the use of animal-derived components.
Precautions
This product is for research/laboratory use. THIS PRODUCT
IS NOT INTENDED FOR HUMAN OR THERAPEUTIC USE.
Storage
Long™R3IGF-I in lyophilized form should be stored at 2 to 8 C and is stable for at least 3 years. Liquid solutions of Long™R3IGF-I (prepared as described below) can be stored
at 2 to 8 C and are stable for at least 2 years.
Preparation Instructions
1. Long™R3IGF-I is supplied lyophilized in an atmosphere of nitrogen at a slight vacuum (-25 kPa). Remove the metal cap from the glass vial and introduce an air filled syringe
through the septum to equalize the pressure.
2. Add sufficient 10 mM HCl or 100 mM acetic acid solution to the vial to achieve a peptide concentration of at least 0.1 mg/mL. Concentrations of 1 mg/mL or more are recommended.
3. Mix the solution thoroughly to insure the peptide is completely dissolved.
4. Filtration of a Long™R3IGF-I solution or a culture medium after the addition of Long™R3IGF-I should be performed using a low protein-binding membrane such as Polyvinyl Idene Flouride (PVDF), Poly Ethylene Sulfite (PES) or Cellulose Acetate (CA).
Methods for Use
Once Long™R3IGF-I has been reconstituted, it can then be added directly to cell culture medium. A titration of Long™R3IGF-I should be performed for each different application as the optimum concentration may vary depending upon the cell type used and other components present in the medium. The recommended final concentration range of Long™R3IGF-I is 10 to 50 µg/L (or ng/mL). Because Long™R3IGF-I and insulin may compete for the same cell receptors, the effectiveness of Long™R3IGF-I will be masked if it is added in conjunction with commonly employed concentrations of insulin (1 to 10 mg/L). However, inclusion of physiological levels of insulin (5 to 10 µg/L) in cell culture medium containing the recommended levels of
Long™R3IGF-I results in beneficial synergistic effects in certain applications.
Characteristics
Appearance
White powder
Molecular weight
9110 ± 2 daltons (Mass spectroscopy)
Endotoxin
< 0.1 EU/µg
Biological Activity
ED50 < 10 ng/mL (Bioassay assessing the stimulation of
protein synthesis in L6 myoblasts)
Identity/Consistency
Confirmed by N-terminal sequence analysis and HPLC
References
1. Francis, G., et al. J. Mol. Endocrinol. (1992) 8:213.
2. Thomas, J., Fung, V. Animal Cell Technology: Products of
Today, Prospects for Tomorrow (1993) 91.
3. Morris, A., Schmid, J. Biotechnol. Prog. (2000) 16:693.
JohnnyB
Recombinant analog of human insulin growth factor-I
CATALOG NO. 85580
Description
Long™R3IGF-I is a recombinant analog of human insulin-like growth factor-I (IGF-I) that has been specifically engineered for the enhancement of cell culture performance. Long™R3IGF-I is more biologically potent in vitro than either insulin or native IGF-I and has been documented to
significantly increase recombinant protein production. It is ideal for both research and large-scale culture systems utilizing serum-free or low-level serum applications. Long™R3IGF-I is effective in any cell that contains type I IGF receptors, including most Chinese Hamster Ovary (CHO) lines, hybridomas and fibroblasts. Long™R3IGF-I is produced in a patented E. coli expression system without the use of animal-derived components.
Precautions
This product is for research/laboratory use. THIS PRODUCT
IS NOT INTENDED FOR HUMAN OR THERAPEUTIC USE.
Storage
Long™R3IGF-I in lyophilized form should be stored at 2 to 8 C and is stable for at least 3 years. Liquid solutions of Long™R3IGF-I (prepared as described below) can be stored
at 2 to 8 C and are stable for at least 2 years.
Preparation Instructions
1. Long™R3IGF-I is supplied lyophilized in an atmosphere of nitrogen at a slight vacuum (-25 kPa). Remove the metal cap from the glass vial and introduce an air filled syringe
through the septum to equalize the pressure.
2. Add sufficient 10 mM HCl or 100 mM acetic acid solution to the vial to achieve a peptide concentration of at least 0.1 mg/mL. Concentrations of 1 mg/mL or more are recommended.
3. Mix the solution thoroughly to insure the peptide is completely dissolved.
4. Filtration of a Long™R3IGF-I solution or a culture medium after the addition of Long™R3IGF-I should be performed using a low protein-binding membrane such as Polyvinyl Idene Flouride (PVDF), Poly Ethylene Sulfite (PES) or Cellulose Acetate (CA).
Methods for Use
Once Long™R3IGF-I has been reconstituted, it can then be added directly to cell culture medium. A titration of Long™R3IGF-I should be performed for each different application as the optimum concentration may vary depending upon the cell type used and other components present in the medium. The recommended final concentration range of Long™R3IGF-I is 10 to 50 µg/L (or ng/mL). Because Long™R3IGF-I and insulin may compete for the same cell receptors, the effectiveness of Long™R3IGF-I will be masked if it is added in conjunction with commonly employed concentrations of insulin (1 to 10 mg/L). However, inclusion of physiological levels of insulin (5 to 10 µg/L) in cell culture medium containing the recommended levels of
Long™R3IGF-I results in beneficial synergistic effects in certain applications.
Characteristics
Appearance
White powder
Molecular weight
9110 ± 2 daltons (Mass spectroscopy)
Endotoxin
< 0.1 EU/µg
Biological Activity
ED50 < 10 ng/mL (Bioassay assessing the stimulation of
protein synthesis in L6 myoblasts)
Identity/Consistency
Confirmed by N-terminal sequence analysis and HPLC
References
1. Francis, G., et al. J. Mol. Endocrinol. (1992) 8:213.
2. Thomas, J., Fung, V. Animal Cell Technology: Products of
Today, Prospects for Tomorrow (1993) 91.
3. Morris, A., Schmid, J. Biotechnol. Prog. (2000) 16:693.
JohnnyB
